Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd Expands Globally with Key Acquisitions & Strong FY26 Growth 📈

- Q4 FY26 revenue grew 17% YoY to ₹44.23 Cr, with EBITDA up 20.7% YoY to ₹19.36 Cr.

- Acquired 13 Sanofi brands (TB & anti-infectives) for ~€158 Mn, expanding reach to 55+ countries.

- Agreed to buy Japan’s MicroBiopharm for ~₹1,300 Cr (JPY 21.5 Bn), boosting oncology & CDMO capabilities.

- FY26 revenue rose 9.96% to ₹165.82 Cr, with EBITDA margin at 45.55% and PAT margin at 28.15%.

- Investing in R&D (9% of revenue) and an 18 MW hybrid renewable power plant to cut costs & emissions.

- New API & R&D units operational, with plans for further geographical and product diversification.